Larimar Therapeutics
Update in progressLRMR (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Larimar Therapeutics is a clinical-stage biotechnology company developing therapies for rare diseases using its cell-penetrating peptide platform. Its lead candidate, CTI-1601, is in a Phase 2 open-label extension study for Friedreich's ataxia, a rare progressive neurodegenerative disorder. Headquartered in Bala Cynwyd, Pennsylvania, the company focuses on advancing targeted treatments where few options exist and seeks to address unmet genetic disease needs.
Company score
- Sentiment
- 0.23
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Carole S. Ben-Maimon M.D.
- Employees71
- Websitewww.larimartx.com
Identifiers
- ISINUS5171251003
- FIGIBBG001J2NVH0
- LEI529900NCBZHTTJV6HX73
- CUSIP517125100
- CIK0001374690